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Patients with pancreatic ductal adenocarcinoma (PDAC) are frequently 
complicated with metastatic disease or locally advanced tumors, and consequently 
need chemotherapy. Gemcitabine is commonly used for PDAC treatment, but with 
limited efficacy. The capacity of gemcitabine to generate reactive oxygen species 
(ROS) in human pancreatic cancer cells, prompted us to examine its effects of the 
expression of pro-inflammatory cytokines and chemokines. We observed that 
gemcitabine enhanced selectively the expression of CXCL8 in human pancreatic 
cancer cells through ROS generation and NF-κB activation. In vitro blocking of 
CXCL8 failed to modulate gemcitabine-mediated inhibition of cell proliferation in 
human pancreatic cancer cells. Gemcitabine also enhanced CXCL8 expression in 
pancreatic cancer cells in xenografted tumor tissues. Moreover, anti-CXCL8 
antibody treatment in vivo attenuated tumor formation as well as intra-tumoral 
vascularity in nude mice, which were transplanted with Miapaca-2 cells and 
treated with gemcitabine. Thus, gemcitabine-induced CXCL8 may counteract the 
drug through inducing neovascularization. 
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Pancreatic ductal adenocarcinoma (PDAC) is a tumor within the exocrine 
compartment of pancreatic gland [1]. About 80% PDAC cases are diagnosed with 
metastatic disease or with locally invasive tumors, and are subjected to 
chemotherapy. The rest of the patients are eligible for curative resection, but 
frequently develop local recurrence or distant metastasis after surgery. As a 
consequence, they also need chemotherapy. 
Gemcitabine, an analogue of cytosine arabinoside (Ara-C) [2], is used as a 
standard drug for PDAC treatment, alone or in combination with other 
chemotherapeutics [1, 3]. Gemcitabine is transported into cells across the cell 
membrane through multiple active nucleoside transporters [4], and is 
phosphorylated by deoxycytidine kinase to produce gemcitabine monophosphate 
(dFdCMP), which is further converted to active drug metabolites, gemcitabine 
diphosphate (dFdCDP) and gemcitabine triphophage (dFdCTP) [5]. dFdCTP 
directly inhibits DNA polymerase [6], cytidine triphosphate synthetase [7] and 
deoxycytidylate deaminase [8], and is incorporated into DNA, thereby terminating 
chain elongation.[9]. dFdCDP potently inhibits ribonucleotide reductase (RR), 
thereby decreasing deoxynucleotide pools [10]. Despite its multiple intracellular 
targets, the resistance to gemcitabine often ensues [1].  
Evidence is accumulating to indicate that gemcitabine induced reactive 
oxygen species (ROS) generation [11]. Moreover, the resultant ROS activated a 
transcription factor NF-κB [11], which has a crucial role in the activation of 
various pro-inflammatory genes, including cytokine and chemokine genes [12]. 
Consistently, we observed that gemcitabine induced ROS generation in a human 
pancreatic cancer cell line, Miapaca-2. Hence, we evaluated the effects of 
gemcitabine on chemokine and cytokine expression in human pancreatic cancer 
cell lines. Indeed, gemcitabine induced abundant expression of CXCL8 in human 
pancreatic cancer cells in vivo as well as in vitro. Moreover, 
endogenously-produced CXCL8 has few effects on gemcitabine-mediated 
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inhibition of in vitro cell proliferation of pancreatic cancer cells. However, 





Materials and Methods 
 
Cell lines and reagents 
Miapaca-2 and Panc-1 cells were obtained from ATCC and were maintained in 
RPMI-1640 medium supplemented with 10% fetal bovine serum. Mouse 
anti-human CXCL8 monoclonal and rabbit anti-human CXCL8 polyclonal 
antibody were prepared as described previously [13]. The following antibodies 
were obtained commercially: rabbit anti-NF-κB/p65 polyclonal antibodies (Cell 
Signaling Technology, Beverly, MA); mouse IgG1 (Sigma-Aldrich, St. Louis, 
MO); rabbit immunoglobulin fraction (Dako, Glostrup, Denmark). N-acetyl 
cysteine (NAC) and gemcitabine were obtained from Sigma Aldrich. 
 
Determination of intracellular ROS concentration by a flow cytometry 
Intracellular ROS concentration was determined by using total ROS/superoxide 
detection kit (Enzo Life Science, San Diego, CA) according to the manufacturer’s 
instructions. In brief, after Miapaca-2 cells were pre-treated with or without NAC 
(30 mM) for 1 hr, the cells were further incubated in the absence or the presence of 
gemcitabine (10 μM) for 24 hr. Then, the cells were collected and incubated with 
ROS/superoxide detection solution for 10 min at 37oC. At least 50,000 stained 
cells were analyzed on a FACSCanto II system (Becton Dickinson, Bedford, MA) 
by using 490 nm and 525 nm wave lengths as excitation and emission wave 
lengths, respectively, for each determination. 
 
In vitro cell proliferation 
Cell suspensions (2 × 103 cells /100 μl) were added to a well of 96-multi-well 
plates and incubated at 37oC for 24 hr. Then, the cells were treated with the 
indicated concentrations of gemcitabine for the indicated time intervals. The cell 
viability was determined by using the cell counting kit-8 (Dojindo Co. Ltd., 
Kumamoto, Japan). The ratios of cell numbers were determined by comparing the 
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cell numbers at day 0. 
 
Assays of secreted CXCL8 
Culture supernatants were collected from Miapaca-2 or Panc-1 cells at the 
indicated time intervals after gemcitabine treatment, to determine CXCL8 contents 
by using enzyme-linked immunosorbent assay (ELISA) for human CXCL8 (R&D 
Systems, Minneapolis, MN). 
 
Transfection of CXCL8 siRNA 
Miapaca-2 or Panc-1 cells were seeded at a density of 1 × 105 cells/well in 2 ml in 
a 6-well plate. After overnight incubation, CXCL8 or control siRNA (Santa Cruz 
Biotechnology, Santa Cruz, CA) was transduced into Miapaca-2 and Panc-1 cells 
using a JetPRIME DNA & siRNA transfection reagent (Polyplus Transfections, 
Illkirch, Germany) and siRNA transfection reagent (Santa Cruz Biotechnology), 
respectively. The cells were then incubated with or without gemcitabine (10 μM) 
for 48 hr and were subjected to proliferation assay or total RNA extraction. 
 
RNA isolation for RT-PCR 
Total RNA was isolated and was reverse transcribed to cDNA as previously 
described [14]. The resultant cDNA was amplified to detect human CXCR1 and 
CXCR2 mRNA by using the specific sets of the primers, 
5’-CCCCTGTATGCTAGAAACTGAGAC-3’ (CXCR1 forward), 
5’-CCAGCAGCCAAGACAAACAAAC-3’ (CXCR1 reverse), 
5’-CATGGGCAACAATACAGCAA-3’ (CXCR2 forward) and 
5’-TGAGGACGACAGCAAAGATG-3’ (CXCR2 reverse) with 30 cycles 
consisting of 94oC for 30 s, 55oC for 30 s and 68oC for 1 min, and with a final 
extension at 68oC for 5 min. Amplified DNA fragments were resolved by 
electrophoresis on 2 % agarose gels and visualized by ethidium bromide staining 
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under ultraviolet light transillumination. GAPDH was used as a positive control. 
Quantitative (q)RT-PCR for CXCL8 was performed using the sets of the primers, 
5’-TGGCAGCCTTCCTGATTTCT-3’ (forward) and 
5’-TTTCTGTGTTGGCGCAGTGT-3’ (reverse) and mRNA amounts were 




Miapaca-2 cells were cultured at a concentration of 1 × 105 cells/well in a 6-well 
plate for 24 hr. Then, the cells were transfected with the luciferase expression 
vectors containing various deleted or mutated 5’-flanking region of the CXCL8 
promoter  [15] (1.5 μg) and SV40-renilla luciferase expression vector (37.5 ng) as 
a control by using a JetPRIME DNA & siRNA transfection reagent. Cells were 
incubated for additional 48 hr with or without gemcitabine (10 μM). Thereafter, 
the cells were harvested to determine luciferase activities with the use of the Dual 
Luciferase Reporter Assay System (Promega, Madison, WI). Firefly luciferase 
values were normalized to Renilla luciferase activities. 
 
Chromatin immunoprecipitation (ChIP) assay. 
ChIP assay was performed using the ChIP assay kit (Upstate Biotechnology, Lake 
Placid, NY). Miapaca-2 cells were cross-linked with 1 % formaldehyde for 10 min 
at 37oC and harvested in sodium dodecyl sulfate lysis buffer. The resultant 
chromatin was sheared to generate fragments of about 500 bp by sonication. Then, 
each aliquot of chromatin received anti-p65 (Cell Signaling Technology) or 
control antibodies, and was incubated at 4oC overnight. The mixtures received 
Protein A agarose (Life Technology, Carlsbad, CA) and were incubated for 
additional 1 hr at 4oC. DNA was recovered by phenol–chloroform extraction 
followed by ethanol precipitation. The resultant DNA underwent PCR using the 
sets of the primers, 5’-GGAACAAATAGGAAGTGTGATGAC-3’ (forward) and 
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5’-AGAGAACTTATGCACCCTCATCT-3’ (reverse), to amplify the 112 bp-long 
fragment, which contains the NF-κB/p65 binding site in the human CXCL8 
promoter, under the conditions consisting of an initial denaturation at 94oC for 5 
min followed by 28 cycles of 94oC for 30 s, 55oC for 30 s, and 68oC for 1 min, 
with a final extension at 68oC for 5 min. The resultant PCR products were 
fractionated on 12 % polyacrylamide gel and visualized by ethidium bromide 
staining under ultraviolet light transillumination. 
 
Animal experiments 
Miapaca-2 cells were suspended in HBSS at a concentration of 3.5 x 107 cells/ml 
and 200 µl cell suspensions were injected subcutaneously into the back of BALB/c 
nu/nu mice (SLC, Shizuoka, Japan). After the tumor size reached 100 mm3, 
gemcitabine (30 mg/kg body weight) was administered four times on day 1, 5, 8, 
and 12, while anti-human CXCL8 monoclonal antibody or control antibody (100 
µg/body) was given four times on day 0, 4, 7, and 11. Tumor sizes were 
determined every 3 to 4 days and its volumes were calculated as follows. Tumor 
volume (mm3) = (the longest diameter) (mm) x (the shortest diameter)2 (mm) / 2. 
At the indicated time points after the injection, tumors were removed for 
immunohistochemical analysis using anti-human CXCL8, anti-mouse CD31 
(Abcam, Cambridge, UK), or anti-mouse Ly6G antibody (BD Biosciences) as 
previously described [14]. All animal experiments were performed in compliance 




Data was analyzed statistically using methods indicated in each figure legend. p< 






Gemcitabine-induced CXCL8 expression in pancreatic cancer cells 
Consistent with the previous report [11], gemcitabine induced ROS generation in 
Miapaca-2 cells (Figure 1A). Given the capacity of ROS to activate NF-κB [16] 
with a crucial role in the expression of pro-inflammatory cytokines and 
chemokines [9], we examined the effects of gemcitabine on the expression of 
pro-inflammatory cytokines and chemokines including interleukin (IL)-1, IL-6, 
CXCL8/IL-8, CXCL1, CCL2/monocyte chemoattractant protein (MCP)-1, 
CCL3/macrophage inflammatory protein (MIP)-1α, CCL4/MIP-1β, CCL7/MCP-3, 
CCL11/eotaxin, and CX3CL1/fractalkine, in Miapaca-2 by using Mutiplex 
immunoassay system. Gemcitabine enhanced selectively IL-8/CXCL8 secretion 
among these molecules in Miapaca-2 cells (data not shown). Consistent with these 
observations, gemcitabine enhanced CXCL8 protein (Figure 1B) and mRNA 
expression in a dose-dependent manner (Figure 1C). Similar observations were 
obtained for another human pancreatic cancer cell line, Panc-1 (data not shown). 
We next examined the effect of a thiol-containing antioxidant, NAC, which is a 
precursor of reduced glutathione, with a capacity to scavenge ROS by interacting 
with OH· and H2O2 [17]. NAC reduced gemcitabine-induced ROS generation 
(Figure 1A) and CXCL8 mRNA expression (Figure 1D). Thus, gemcitabine 
induced CXCL8 expression in human pancreatic cancer cells through ROS 
generation. 
 
Indispensable roles of NF-κB activation in gemcitabine-induced CXCL8 
expression 
Gemcitabine enhanced luciferase activities when Miapaca-2 cells were transduced 
with the reporter gene under the control of the 546, 272 or 133 bp CXCL8 
promoter/enhancer region (Figure 2A and 2B). The mutation in NF-κB binding 
site abrogated the gemcitabine-induced enhancement in luciferase activities, 
whereas the mutation in either AP-1 or NF-IL-6 binding site had minimal effects 
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(Figure 2C). Moreover, ChIP assay revealed that gemcitabine induced the binding 
of a component of NF-κB, p65, to CXCL8 promoter in Miapaca-2 cells (Figure 
2D). Thus, NF-κB activation is indispensable to gemcitabine-induced CXCL8 
expression. 
 
The roles of CXCL8 in gemcitabine-mediated inhibition of cellular 
proliferation 
We could not detect expression of mRNA of specific receptors for CXCL8, 
CXCR1 and CXCR2, in untreated or gemcitabine-treated Miapaca-2 and Panc-1 
cells (Figure 3A). Consistently, flow cytometric analysis failed to detect CXCR1 
and CXCR2 expression on untreated or gemcitabine-treated Miapaca-2 and Panc-1 
cells (data not shown). CXCL8 siRNA efficiently inhibited gemcitabine-induced 
CXCL8 expression (Figure 3B), but failed to modulate gemcitabine-induced 
reduction in cell proliferation in either cell line (Figure 3C). Thus, 
gemcitabine-induced CXCL8 expression had few effects on cellular growth of 
human pancreatic cancer cells in an autocrine manner. 
 
Involvement of gemcitabine-induced CXCL8 expression in in vivo tumor 
growth 
We finally examined the effects of gemcitabine on CXCL8 expression in 
xenotransplanted tumor tissues. Gemcitabine induced CXCL8 mRNA expression 
(data not shown) and CXCL8 protein expression in pancreatic cancer cells in 
xenografted tumor tissues (Figure 4A). We next administered anti-CXCL8 
antibody in combination with gemcitabine after xenografted Miapaca-2 cells 
formed tumor in mice. Tumor growth rates were reduced by the combined 
treatment of gemcitabine and anti-CXCL8 antibody but not with that of either 
single agent (Figure 4B). Anti-CXCL8 antibody failed to reduce Ly6G-positive 
granulocytes (Figure 4C) and F4/80-positive macrophages (data not shown). On 
the contrary, the treatment markedly reduced CD31-positive vascular areas (Figure 
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4D). Thus, gemcitabine enhanced tumor cell-derived CXCL8 expression, which 






CXC chemokines are divided into ELR-positive or ELR-negative CXC 
chemokines on the basis of the 3 amino acid sequence consisting of glutamic 
acid-leucine-arginine (the “ELR” motif) immediately preceding the first cysteine 
residue [18]. Most ELR-positive CXC chemokines utilize selectively CXCR2, 
except for CXCL6 and CXCL8 which utilize CXCR1 as well as CXCR2 [18, 19, 
20]. CXCL8 is a potent chemotactic factor for neutrophils and has a crucial role in 
various types of neutrophil-mediated acute inflammation [21]. CXCR1 and 
CXCR2 are coordinately expressed by human neutrophils [22] and bind CXCL8 to 
induce a group of equipotent responses including chemotaxis and exocytosis [23]. 
However, they couple to distinct G proteins [24] to differentially generate other 
signals such as receptor internalization and phospholipase D activation [23] and 
these signals are required for full responsiveness of human neutrophils to CXCL8. 
Because mice do not possess the functional CXCR1 genes [25], human CXCL8 
produced by gemcitabine-treated human cancer cells, could not fully induce mouse 
neutrophil responses and as a consequence, anti-CXCL8 antibody failed to reduce 
neutrophil infiltration under these conditions. 
Tumor growth depends on the interaction with tumor microenvironment 
consisting of non-leukocytic cells including endothelial cells and fibroblasts as 
well as leukocytes [26]. Tumor microenvironment is influenced by various 
inflammatory molecules. Gemcitabine induced a robust production of CXCL8 in 
Miapaca-2 and Panc-1 cells. This chemokine can promote the migration and 
proliferation of endothelial cells, after binding mainly CXCR2 expressed by 
endothelial cells [27, 28]. Moreover, accumulating evidence indicates the crucial 
roles of CXCL8 in tumor neovascularization in several animal tumor models, as 
evidenced by reduced tumor angiogenesis by CXCL8 blockade [29, 30]. Likewise, 
we observed that anti-CXCL8 antibody treatment reduced intra-tumoral 
neovascularization as well as tumor sizes in mice treated with gemcitabine. Thus, 
gemcitabine treatment may counteract its anti-tumor effects by inducing a potent 
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angiogenic factor, CXCL8, and CXCL8 blockade may be effective to enhance the 
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Legends to Figures 
 
 
Figure 1. Gemcitabine-induced CXCL8 expression in human pancreatic cancer 
cell lines. A. Miapaca-2 cells were incubated in the absence or the presence 
gemcitabine for 24 hr with 1 hr pretreatment with NAC. Then, intracellular ROS 
levels were determined. Representative results from 3 independent experiments 
are shown here. B and C. Miapaca-2 cells were treated with the indicated 
concentrations of gemcitabine for 24 or 48 hr. Supernatants were collected to 
determine CXCL8 contents by using a specific ELISA for human CXCL8 (B) 
while total RNA was extracted to determine CXCL8 mRNA levels by qRT-PCR 
(C). Mean and 1 SE were calculated for 3 independent experiments and are shown. 
*, p<0.05; **, p<0.01 using one-way ANOVA followed by the Dunnett test, 
compared with untreated. D. Miapaca-2 cells were incubated in the absence or the 
presence of gemcitabine for 48 hr after 1 hr pretreatment with NAC. Total RNA 
was extracted to conduct qRT-PCR to determine CXCL8 mRNA levels. Mean and 
1SE were calculated for 3 independent experiments and are shown here. **, 
p<0.01 using Student’s t-test. 
 
Figure 2. Crucial roles of NF-κB activation in gemcitabine-induced CXCL8 
expression. A. Schematic structure of 5’ promoter/enhancer region of human 
CXCL8 gene and luciferase expression linked with deleted or mutated 5’ promoter 
region of human CXCL8 gene. B and C. The cells were transiently transfected 
with CXCL8 promoter/enhancer-driven luciferase expression vectors together with 
SV40-renilla luciferase expression vector. After the cells were treated with or 
without gemcitabine for 48 hr, they were harvested to determine their luciferase 
activities. Mean and 1 SE calculated for 3 independent experiments are shown. D. 
ChIP assay was conducted. Input indicates the results when total nuclear lysates 
were used without any immunoprecipitation. Representative results from 3 
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independent experiments are shown. 
 
Figure 3. Roles of CXCL8 in gemcitabine-induced inhibition of cell proliferation. 
A Miapaca-2 cells (upper panels) and Panc-1 cells (lower panels) were treated 
with the indicated concentrations of gemcitabine for the indicated time intervals. 
Cells were then harvested and subjected to RT-PCR analysis to detect CXCR1 or 
CXCR2 mRNA expression. Representative results from 3 independent 
experiments are shown here. B and C. Miapaca-2cells (left panels) or Panc-1 cells 
(right panels) were transfected with CXCL8 or control siRNA. CXCL8 mRNA 
expression was determined by using qRT-PCR (B). The transfected cells were 
incubated with the indicated concentrations of gemcitabine for 48 hr. Cell viability 
was determined (C). Mean and 1 SE were calculated for 3 independent 
experiments and are shown here. *, p<0.05; **, p<0.01 using Student’s t-test. 
 
Figure 4. Gemcitabine-induced CXCL8 expression in xenotransplanted tumor 
tissues. A. Miapaca-2 cells (7 x 106) were subcutaneously injected into nude mice. 
After tumor was formed, gemcitabine (30 mg/kg) or PBS was administered 
intraperitoneally every 3 days. Tumor tissues were obtained 7 or 14 days after the 
start of gemcitabine treatment and were subjected to immunohistochemical 
analysis using anti-human CXCL8. Representative results from 3 independent 
animals are shown here with a scale bar of 100 µm. B. Tumor volumes were 
determined every 3 to 4 days after the initiation of gemcitabine and/or 
anti-CXCL8 antibody treatment. Each group consists of at least 10 tumors. Mean 
and 1 SE were calculated for 3 independent experiments and are shown here. *, 
p<0.05, using one-way ANOVA, followed by the Tukey-Kramer test. C and D. At 
14 days after the initiation of gemcitabine and/or anti-CXCL8 antibody treatment, 
tumors were removed and subjected to immunohistochemical analysis using 
anti-Ly6G (C) or anti-CD31 antibodies (D). Ly6G-postive cell numbers (C) or 
CD31-positive areas (D) were determined. Mean and 1 SE were calculated for 3 
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individual samples and are shown. *, p<0.05 using one-way ANOVA, followed by 
the Tukey-Kramer test. 




